Abstract: To provide hollow silica particles having a dense silica shell layer. A method for producing hollow silica particles, which comprises: adjusting the pH of an oil-in-water emulsion containing an aqueous phase, an oil phase and a surfactant to at most 3.0 and adding a first silica material to the oil-in-water emulsion, adding a second silica material to the emulsion having the first silica material added, at its pH of at least 8, in the presence of alkali metal ions, to obtain a hollow silica precursor dispersion, and obtaining a hollow silica precursor from the hollow silica precursor dispersion and obtaining hollow silica particles from the hollow silica precursor.

Abstract: To provide hollow silica particles having a dense silica shell layer. A method for producing hollow silica particles, which comprises: adjusting the pH of an oil-in-water emulsion containing an aqueous phase, an oil phase and a surfactant to at most 3.0 and adding a first silica material to the oil-in-water emulsion, adding a second silica material to the emulsion having the first silica material added, at its pH of at least 8, in the presence of alkali metal ions, to obtain a hollow silica precursor dispersion, and obtaining a hollow silica precursor from the hollow silica precursor dispersion and obtaining hollow silica particles from the hollow silica precursor.

Abstract: The present invention is a method for detecting a specific disease based on the result of a measurement in which the amount of a peptide serving as a biomarker contained in a biological sample is determined by using an LC-MS. A pretreatment process performed before the measurement using the LC-MS includes the steps of preparing a mixed sample solution by adding a stable isotope reagent and a trifluoroacetic acid to the biological sample, where the stable isotope reagent is prepared beforehand by labeling the peptide with a stable isotope; boiling the mixed sample solution; injecting the mixed sample solution after boiled into a solid-phase extraction column to make the peptide be retained in the solid-phase extraction column; and passing a water-soluble organic solvent through the solid-phase extraction column to elute the peptide retained in the solid-phase extraction column and collect the eluate.

Abstract: The present invention related to a hollow silica particle including: a shell layer containing silica; and a space formed inside the shell layer, in which the hollow silica particle has a particle density as measured by a dry pycnometer density measurement using helium gas of 2.00 g/cm3 or more and a particle density as measured by a dry pycnometer density measurement using oxygen gas of lower than 2.00 g/cm3.

Abstract: In a chromatograph mass spectrometer having a measurement unit (1) including a chromatograph is combined with a tandem mass spectrometry section capable of an MS/MS analysis, a controller (40) performs chromatograph mass spectrometry by controlling the measurement unit so as to operate the tandem mass spectrometry section to cyclically perform analysis cycles, where each of the analysis cycles includes a first mass spectrometric analysis in which a measurement of ions is performed over a predetermined m/z range and an MS/MS analysis by DIA in which ions included within each of a plurality of windows formed by dividing the m/z range are designated as a precursor ion. A window selector (42, 43) selects, during an execution of an analysis cycle, a window among the plurality of windows for an MS/MS analysis by DDA which is irregularly performed in an ongoing analysis cycle, based on intensity information obtained for each of the plurality of windows from an MS/MS spectrum acquired by the MS/MS analysis by DIA.

Abstract: In a chromatograph mass spectrometer having a measurement unit (1) including a chromatograph is combined with a tandem mass spectrometry section capable of an MS/MS analysis, a controller (40) performs chromatograph mass spectrometry by controlling the measurement unit so as to operate the tandem mass spectrometry section to cyclically perform analysis cycles, where each of the analysis cycles includes a first mass spectrometric analysis in which a measurement of ions is performed over a predetermined m/z range and an MS/MS analysis by DIA in which ions included within each of a plurality of windows formed by dividing the m/z range are designated as a precursor ion. A window selector (42, 43) selects, during an execution of an analysis cycle, a window among the plurality of windows for an MS/MS analysis by DDA which is irregularly performed in an ongoing analysis cycle, based on intensity information obtained for each of the plurality of windows from an MS/MS spectrum acquired by the MS/MS analysis by DIA.

Abstract: The present invention provides a method for pretreatment of a biological sample in order to measure a protein contained in the biological sample by liquid chromatography/mass spectrometry. The method includes the step of adding an acetic acid aqueous solution to the biological sample, so as to prepare a pretreatment sample containing an acetic acid at a concentration ranging from 20 to 50 weight percent, both inclusive. In the present invention, a target protein contained in a biological sample is less prone to be adsorbed to a sample container, thereby resulting in an increased sensitivity of measuring the protein in the biological sample by mass spectrometry. Further, reproducibility of results of the mass spectrometry is improved, and reliability is increased.

Abstract: The present invention is a method for detecting a specific disease based on the result of a measurement in which the amount of a peptide serving as a biomarker contained in a biological sample is determined by using an LC-MS. A pretreatment process performed before the measurement using the LC-MS includes the steps of preparing a mixed sample solution by adding a stable isotope reagent and a trifluoroacetic acid to the biological sample, where the stable isotope reagent is prepared beforehand by labeling the peptide with a stable isotope; boiling the mixed sample solution; injecting the mixed sample solution after boiled into a solid-phase extraction column to make the peptide be retained in the solid-phase extraction column; and passing a water-soluble organic solvent through the solid-phase extraction column to elute the peptide retained in the solid-phase extraction column and collect the eluate.

Abstract: The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. A method for analyzing colon cancer markers using multiplex colon cancer marker panel.

Abstract: To provide hollow silica particles having a dense silica shell layer. A method for producing hollow silica particles, which comprises: adjusting the pH of an oil-in-water emulsion containing an aqueous phase, an oil phase and a surfactant to at most 3.0 and adding a first silica material to the oil-in-water emulsion, adding a second silica material to the emulsion having the first silica material added, at its pH of at least 8, in the presence of alkali metal ions, to obtain a hollow silica precursor dispersion, and obtaining a hollow silica precursor from the hollow silica precursor dispersion and obtaining hollow silica particles from the hollow silica precursor.

Abstract: In the present invention, multiple reaction monitoring (MRM) measurements of at least one peptide selected from the group consisting of 14 peptides as biomarkers of cognitive dysfunction diseases contained in a biological sample are performed using a mass spectrometer capable of MS/MS measurement, and the peptide is quantified based on a result thereof. In this case, for each peptide, an MRM transition which is a combination of a mass-to-charge ratio of a precursor ion and a mass-to-charge ratio of a product ion is stored in advance in a storage unit of the mass spectrometer as a measurement condition of the MRM measurement, and the MRM transition is used when cognitive dysfunction disease biomarkers are detected.

Abstract: The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. A method for analyzing colon cancer markers using multiplex colon cancer marker panel.

Abstract: An insulin resistance marker, a method of evaluating insulin resistance, a method of screening a substance that improves insulin resistance, and a pharmaceutical composition for improving insulin resistance are provided. The insulin resistance marker includes a polypeptide comprising at least any 15 continuous amino acids in the specific amino acid sequence of SEQ ID NO: 1 (sequence of a proepithelin protein). The insulin resistance marker includes a polynucleotide selected from the group consisting of (1) a polynucleotide comprising at least any 45 continuous bases in the base sequence of SEQ ID NO:2 encoding the above specific amino acid sequence, and (2) a polynucleotide that is complementary to the polynucleotide of (1).

Abstract: The present invention provides a marker capable of detecting insulin resistance and diabetes in a collected blood sample, a method for analyzing said marker, a method for screening a substance improving insulin resistance, and improving or suppressing diabetes. A blood insulin resistance marker and a blood diabetes marker, which comprises a polypeptide comprising at least 15 continuous amino acids in an amino acid sequence constituting progranulin. A method for analyzing a blood marker, which comprises the steps of: measuring a concentration of an insulin resistance marker or a diabetes marker in a collected blood sample; and comparing the measured concentration with a normal blood concentration of the marker.

Abstract: The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Vitronectin for use as a tumor progression marker, a tumor screening marker or a prognostic prediction marker for colorectal cancer. A method of analyzing a vitronectin concentration in a collected blood sample. In the method, a measured value of vitronectin and a reference value of vitronectin are compared. Vitronectin is preferably used in combination with existing marker for colorectal cancer such as carcinoembryonic antigen and CA19-9.

Abstract: The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody.

Abstract: It is provided an insulin resistance marker, a method of evaluating insulin resistance, a method of screening a substance that improves insulin resistance, and a pharmaceutical composition for improving insulin resistance. An insulin resistance marker including a polypeptide comprising at least any 15 continuous amino acids in the specific amino acid sequence (sequence of a proepithelin protein). An insulin resistance marker including a polynucleotide selected from the group consisting of a polynucleotide comprising at least any 45 continuous bases in the base sequence encoding the above specific amino acid sequence, and a polynucleotide that is complementary to the polynucleotide.

Abstract: It is provided an insulin resistance marker, a method of evaluating insulin resistance, a method of screening a substance that improves insulin resistance, and a pharmaceutical composition for improving insulin resistance. An insulin resistance marker including a polypeptide comprising at least any 15 continuous amino acids in the specific amino acid sequence (sequence of a proepithelin protein). An insulin resistance marker including a polynucleotide selected from the group consisting of a polynucleotide comprising at least any 45 continuous bases in the base sequence encoding the above specific amino acid sequence, and a polynucleotide that is complementary to the polynucleotide.

Abstract: The present invention provides a tumor marker and a method capable of identifying the morbidity of colon cancer. A tumor marker including a protein identified from a colon cancer tissue. A method for identify the morbidity of colon cancer using the tumor marker. The method includes: measuring the level of the protein in a sample derived from a person of interest who should be examined to identify the morbidity of colon cancer; and comparing the measured level to the normal level of the protein, wherein a higher or lower measured level than the normal level is used as one indicator indicating that there is a high possibility that the person of interest has colon cancer.

Abstract: A process for producing inorganic spheres, which comprises injecting an aqueous liquid containing an inorganic compound into a laminar flow of an organic liquid which runs at a flow rate of from 0.001 to 2 m/s in a flow path compartmentalized by a partition wall through a plurality of inlet holes formed in one partition wall to form a W/O type emulsion containing the organic liquid as a dispersion medium and the aqueous liquid containing the inorganic compound as a dispersed phase, and solidifying the aqueous liquid containing an inorganic compound in the W/O type emulsion, wherein the partition wall having a plurality of inlet holes is made of a metal sheet having a surface subjected to water repellent treatment.